Stockscreener 앱 받기
5.53
3.32%
-0.19
전일 마감가:
$5.72
열려 있는:
$5.67
하루 거래량:
1.01M
Relative Volume:
0.43
시가총액:
$1.13B
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-16.76
EPS:
-0.33
순현금흐름:
$-51.36M
1주 성능:
-1.25%
1개월 성능:
-7.37%
6개월 성능:
+78.96%
1년 성능:
+105.58%
1일 변동 폭
$5.485
$5.74
1주일 범위
$5.44
$5.86
52주 변동 폭
$1.89
$7.005
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.53 | 1.16B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
FDA accepts Savara’s drug application for rare lung disease - Investing.com India
FDA accepts Savara’s drug application for rare lung disease By Investing.com - Investing.com South Africa
Savara's Molbreevi BLA for Autoimmune Pulmonary Alveolar Proteinosis Accepted for FDA Review - marketscreener.com
Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA - GuruFocus
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA - GuruFocus
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - The AI Journal
Chart Watch: Whats the fair value of Savara Inc stockStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach - TipRanks
GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA - MarketBeat
Savara (SVRA) Is Up 7.1% After BLA Resubmission And Pricing Reveal For Lead aPAP TherapyHas The Bull Case Changed? - simplywall.st
Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit - MarketBeat
Risk Check: Whats the fair value of Savara Inc stockQuarterly Earnings Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
What dividend safety score for Savara Inc. stockEarnings Growth Report & Safe Entry Point Identification - mfd.ru
Savara Announces New Employment Inducement Grant - The Joplin Globe
Savara, Inc. (SVRA) Stock Analysis: Exploring an 85% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Savara (NASDAQ:SVRA) Shares Up 6.8%Here's Why - MarketBeat
Growth Value: Is Savara Inc being accumulated by smart moneyEarnings Trend Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Savara Insiders Added US$535.6k Of Stock To Their Holdings - Yahoo Finance
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug - MyChesCo
Savara Announces Participation in Upcoming February 2026 Investor Healthcare Conferences - BioSpace
Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Savara Announces Participation in Upcoming Investor Healthcare Conferences - ChartMill
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara (NASDAQ:SVRA) Trading 2.5% HigherShould You Buy? - MarketBeat
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA) - simplywall.st
ETF Watch: Why is Savara Inc stock going downQuarterly Performance Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Savara grants equity awards to new hires as it advances rare lung drug - MSN
Growth Report: Is Savara Inc being accumulated by smart moneyQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Movement Recap: Will Savara Inc announce a stock splitStock Surge & AI Enhanced Execution Alerts - baoquankhu1.vn
Savara, Inc. (SVRA) Investor Outlook: Analyst Ratings Signal A Potential 93.77% Upside - DirectorsTalk Interviews
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - BioSpace
Savara secures additional $75m in debt financing for potential drug launch - Investing.com Australia
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case - simplywall.st
A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement - Yahoo Finance
Savara Reports Amendment to Hercules Capital Debt Facility - marketscreener.com
Savara amends loan agreement to access up to $105 million in term loans - Investing.com Nigeria
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit - simplywall.st
Savara Ekes up on Deal with Hercules - Baystreet.ca
Savara amends loan agreement to access up to $105 million in term loans By Investing.com - Investing.com South Africa
Savara Enters New Material Definitive Agreement and Obligation - TipRanks
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses - Intellectia AI
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Savara, Inc. (SVRA) Stock Analysis: Exploring a 67% Potential Upside in Rare Respiratory Disease Biotech - DirectorsTalk Interviews
CEO Moves: Does Star Equity Holdings Inc have a competitive edgeLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal - MSN
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal - mychesco.com
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch - MSN
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사바라 주식 (SVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
0.34%
0.89%
자본화:
|
볼륨(24시간):